Mizuho raised the firm’s price target on McKesson to $450 from $427 and keeps a Neutral rating on the shares post the fiscal Q2 report. While the company maintained fiscal 2024 operating profit guidance, sub-segment guidance shifted with stronger than expected growth in the pharma segment that should offset incremental headwinds in the medical segment, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MCK: